Home > Publications database > Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas. > print

001     303370
005     20250806114414.0
024 7 _ |a 10.1186/s13014-025-02707-7
|2 doi
024 7 _ |a pmid:40745612
|2 pmid
024 7 _ |a pmc:PMC12315396
|2 pmc
037 _ _ |a DKFZ-2025-01619
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Jabbarli, Leyla
|0 0000-0001-7370-5077
|b 0
245 _ _ |a Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.
260 _ _ |a London
|c 2025
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1754393742_8393
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Proprietary bi-nuclide plaques combine the radiation properties of beta and gamma brachytherapy and can irradiate a larger target volume compared to ruthenium-plaques. While reducing the dose to structures outside the target volume, brachytherapy with bi-nuclide-plaques (BBNP) delivers a higher target dose compared to iodine-plaques. We aimed at analyzing the local tumor control and eye retention probability after BBNP.All consecutive cases with large uveal melanoma (tumor thickness ≥ 7 mm) treated with BBNP at our institution between 01/1999 and 12/2020 were included (n = 576, median follow-up: 30.8 months [interquartile range, IQR: 12.9-57.4]). Univariable and multivariable Cox regression analyses were performed.Secondary enucleation (SE) was performed in 13.5% of cases (n = 78) after the median of 20.0 months (IQR: 9.0-34.7) post-BBNP. The overall rate of local tumor recurrence (LR) in the cohort was 8.5% (n = 49) and was diagnosed at the median post-BBNP interval of 20.0 months (IQR: 15.6-35.2). Of the patients' baseline characteristics, higher age (> 67 years, adjusted hazard ratio [aHR] = 1.80, p = 0.011), tumor thickness (> 8.5 mm, aHR = 2.20, p = 0.002), visual acuity (> 0.5 logMAR, aHR = 1.83, p = 0.009), and sclera dose (> 1000 Gy, aHR = 1.65, p = 0.034) were independently associated with the risk of SE. In turn, higher age (> 67 years, aHR = 1.93, p = 0.023), tumor thickness (> 8.5 mm, aHR = 2.02, p = 0.020), and visual acuity (> 0.5 logMAR, aHR = 2.27, p = 0.005) were independently related to LR.BBNP facilitates eye retention in 86.5% of patients with large uveal melanoma 2.5 years after treatment. Patients' baseline, tumor and treatment characteristics were strongly associated with the risk of SE and LR after BBNP.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Bi-nuclide plaque
|2 Other
650 _ 7 |a Brachytherapy
|2 Other
650 _ 7 |a Enucleation
|2 Other
650 _ 7 |a Local recurrence
|2 Other
650 _ 7 |a Risk factors
|2 Other
650 _ 7 |a Uveal melanoma
|2 Other
650 _ 7 |a Iodine Radioisotopes
|2 NLM Chemicals
650 _ 7 |a Ruthenium Radioisotopes
|2 NLM Chemicals
650 _ 7 |a Iodine-125
|0 GVO776611R
|2 NLM Chemicals
650 _ 7 |a Ruthenium-106
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Brachytherapy: methods
|2 MeSH
650 _ 2 |a Uveal Neoplasms: radiotherapy
|2 MeSH
650 _ 2 |a Uveal Neoplasms: pathology
|2 MeSH
650 _ 2 |a Melanoma: radiotherapy
|2 MeSH
650 _ 2 |a Melanoma: pathology
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Iodine Radioisotopes: therapeutic use
|2 MeSH
650 _ 2 |a Uveal Melanoma
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Ruthenium Radioisotopes: therapeutic use
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Follow-Up Studies
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Neoplasm Recurrence, Local: pathology
|2 MeSH
650 _ 2 |a Radiotherapy Dosage
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
700 1 _ |a Fiorentzis, Miltiadis
|b 1
700 1 _ |a Guberina, Maja
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Schmidt, Boerge
|b 3
700 1 _ |a Rating, Philipp
|b 4
700 1 _ |a Biewald, Eva
|b 5
700 1 _ |a Guberina, Nika
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Flühs, Dirk
|b 7
700 1 _ |a Bornfeld, Norbert
|b 8
700 1 _ |a Sauerwein, Wolfgang
|b 9
700 1 _ |a Stuschke, Martin
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Bechrakis, Nikolaos E
|b 11
773 _ _ |a 10.1186/s13014-025-02707-7
|g Vol. 20, no. 1, p. 119
|0 PERI:(DE-600)2224965-5
|n 1
|p 119
|t Radiation oncology
|v 20
|y 2025
|x 1748-717X
909 C O |o oai:inrepo02.dkfz.de:303370
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b RADIAT ONCOL : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:44:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:44:48Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:44:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-18
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21